Universal Vision Biotechnology Co., Ltd.TPEX: 3218

Announcement of FY2021 consolidated financial reports approved by the Board of Directors

· Issued by Universal Vision Biotechnology Co., Ltd.
Close
Today's Information

Provided by: UNIVERSAL VISION BIOTECHNOLOGY CO., LTD.
SEQ_NO 4 Date of announcement 2022/03/30 Time of announcement 21:02:54
Subject
 Announcement of FY2021 consolidated financial reports
approved by the Board of Directors
Date of events 2022/03/30 To which item it meets paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/03/30
2.Date of the audit committee approved:2022/03/30
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):2,631,801
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):1,636,443
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):768,535
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):763,107
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):610,658
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):595,428
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):7.82
11.Total assets end of the period (thousand NTD):3,749,650
12.Total liabilities end of the period
(thousand NTD):1,421,155
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,188,362
14.Any other matters that need to be specified:N/A

Earlier from Universal Vision Biotechnology

All Universal Vision Biotechnology news releases